Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol

INTRODUCTION: Clostridioides difficile is the leading cause of healthcare-associated infections in the USA, with an estimated 1 billion dollars in excess cost to the healthcare system annually. C. difficile infection (CDI) has high recurrence rate, up to 25% after first episode and up to 60% for suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Cirle A, Shin, Jae Hyun, Bansal, Ekta N, Costa, Deiziane V D S, Wang, Xin Qun, Wu, Martin, Swann, Jonathan R, Behm, Brian W, Targonski, Paul V, Archbald-Pannone, Laurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Research Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357635/
https://www.ncbi.nlm.nih.gov/pubmed/37474181
http://dx.doi.org/10.1136/bmjopen-2023-075721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357635/
https://www.ncbi.nlm.nih.gov/pubmed/37474181
http://dx.doi.org/10.1136/bmjopen-2023-075721

Ejemplares similares